218 related articles for article (PubMed ID: 26640770)
1. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal head-to-head comparison of
Chen CD; McCullough A; Gordon B; Joseph-Mathurin N; Flores S; McKay NS; Hobbs DA; Hornbeck R; Fagan AM; Cruchaga C; Goate AM; Perrin RJ; Wang G; Li Y; Shi X; Xiong C; Pontecorvo MJ; Klein G; Su Y; Klunk WE; Jack C; Koeppe R; Snider BJ; Berman SB; Roberson ED; Brosch J; Surti G; Jiménez-Velázquez IZ; Galasko D; Honig LS; Brooks WS; Clarnette R; Wallon D; Dubois B; Pariente J; Pasquier F; Sanchez-Valle R; Shcherbinin S; Higgins I; Tunali I; Masters CL; van Dyck CH; Masellis M; Hsiung R; Gauthier S; Salloway S; Clifford DB; Mills S; Supnet-Bell C; McDade E; Bateman RJ; Benzinger TLS;
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2669-2682. PubMed ID: 37017737
[TBL] [Abstract][Full Text] [Related]
3. Temporal and anatomical distribution of
Yun T; Lee W; Kang JH; Yang MP; Kang BT
BMC Vet Res; 2020 Jan; 16(1):17. PubMed ID: 31952531
[TBL] [Abstract][Full Text] [Related]
4. Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.
Lan MJ; Ogden RT; Kumar D; Stern Y; Parsey RV; Pelton GH; Rubin-Falcone H; Pradhaban G; Zanderigo F; Miller JM; Mann JJ; Devanand DP
J Alzheimers Dis; 2017; 60(3):939-947. PubMed ID: 28984586
[TBL] [Abstract][Full Text] [Related]
5. Generation of synthetic PET images of synaptic density and amyloid from
Wang R; Liu H; Toyonaga T; Shi L; Wu J; Onofrey JA; Tsai YJ; Naganawa M; Ma T; Liu Y; Chen MK; Mecca AP; O'Dell RS; van Dyck CH; Carson RE; Liu C
Med Phys; 2021 Sep; 48(9):5115-5129. PubMed ID: 34224153
[TBL] [Abstract][Full Text] [Related]
6. Impact of simulated reduced injected dose on the assessment of amyloid PET scans.
Young P; Heeman F; Axelsson J; Collij LE; Hitzel A; Sanaat A; Niñerola-Baizan A; Perissinotti A; Lubberink M; Frisoni GB; Zaidi H; Barkhof F; Farrar G; Baker S; Gispert JD; Garibotto V; Rieckmann A; Schöll M;
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):734-748. PubMed ID: 37897616
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus.
Leinonen V; Rinne JO; Wong DF; Wolk DA; Trojanowski JQ; Sherwin PF; Smith A; Heurling K; Su M; Grachev ID
Acta Neuropathol Commun; 2014 Apr; 2():46. PubMed ID: 24755237
[TBL] [Abstract][Full Text] [Related]
8. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.
Gordon BA; Blazey TM; Su Y; Hari-Raj A; Dincer A; Flores S; Christensen J; McDade E; Wang G; Xiong C; Cairns NJ; Hassenstab J; Marcus DS; Fagan AM; Jack CR; Hornbeck RC; Paumier KL; Ances BM; Berman SB; Brickman AM; Cash DM; Chhatwal JP; Correia S; Förster S; Fox NC; Graff-Radford NR; la Fougère C; Levin J; Masters CL; Rossor MN; Salloway S; Saykin AJ; Schofield PR; Thompson PM; Weiner MM; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
Lancet Neurol; 2018 Mar; 17(3):241-250. PubMed ID: 29397305
[TBL] [Abstract][Full Text] [Related]
9. Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer's disease with PET imaging agents
Son HJ; Jeong YJ; Yoon HJ; Lee SY; Choi GE; Park JA; Kim MH; Lee KC; Lee YJ; Kim MK; Cho K; Kang DY
BMC Neurosci; 2018 Jul; 19(1):45. PubMed ID: 30053803
[TBL] [Abstract][Full Text] [Related]
10. Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging.
Lopes Alves I; Heeman F; Collij LE; Salvadó G; Tolboom N; Vilor-Tejedor N; Markiewicz P; Yaqub M; Cash D; Mormino EC; Insel PS; Boellaard R; van Berckel BNM; Lammertsma AA; Barkhof F; Gispert JD
Alzheimers Res Ther; 2021 Apr; 13(1):82. PubMed ID: 33875021
[TBL] [Abstract][Full Text] [Related]
11. Negative 11C-PIB PET Predicts Lack of Alzheimer's Disease Pathology in Postmortem Examination.
Scheinin NM; Gardberg M; Röyttä M; Rinne JO
J Alzheimers Dis; 2018; 63(1):79-85. PubMed ID: 29614642
[TBL] [Abstract][Full Text] [Related]
12. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?
Provenzano FA; Muraskin J; Tosto G; Narkhede A; Wasserman BT; Griffith EY; Guzman VA; Meier IB; Zimmerman ME; Brickman AM;
JAMA Neurol; 2013 Apr; 70(4):455-61. PubMed ID: 23420027
[TBL] [Abstract][Full Text] [Related]
13. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.
Klunk WE; Koeppe RA; Price JC; Benzinger TL; Devous MD; Jagust WJ; Johnson KA; Mathis CA; Minhas D; Pontecorvo MJ; Rowe CC; Skovronsky DM; Mintun MA
Alzheimers Dement; 2015 Jan; 11(1):1-15.e1-4. PubMed ID: 25443857
[TBL] [Abstract][Full Text] [Related]
14. PET/MRI multimodality imaging to evaluate changes in glymphatic system function and biomarkers of Alzheimer's disease.
Okazawa H; Nogami M; Ishida S; Makino A; Mori T; Kiyono Y; Ikawa M
Sci Rep; 2024 May; 14(1):12310. PubMed ID: 38811627
[TBL] [Abstract][Full Text] [Related]
15. High Correlation of Static First-Minute-Frame (FMF) PET Imaging after
Seiffert AP; Gómez-Grande A; Villarejo-Galende A; González-Sánchez M; Bueno H; Gómez EJ; Sánchez-González P
Sensors (Basel); 2021 Jul; 21(15):. PubMed ID: 34372416
[TBL] [Abstract][Full Text] [Related]
16. Early-phase
Boccalini C; Peretti DE; Ribaldi F; Scheffler M; Stampacchia S; Tomczyk S; Rodriguez C; Montandon ML; Haller S; Giannakopoulos P; Frisoni GB; Perani D; Garibotto V
J Nucl Med; 2022 Jul; 64(2):266-73. PubMed ID: 35863896
[No Abstract] [Full Text] [Related]
17. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).
Pilebro B; Arvidsson S; Lindqvist P; Sundström T; Westermark P; Antoni G; Suhr O; Sörensen J
J Nucl Cardiol; 2018 Feb; 25(1):240-248. PubMed ID: 27645889
[TBL] [Abstract][Full Text] [Related]
18. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation.
Roberts RO; Knopman DS; Cha RH; Mielke MM; Pankratz VS; Boeve BF; Kantarci K; Geda YE; Jack CR; Petersen RC; Lowe VJ
J Nucl Med; 2014 May; 55(5):759-64. PubMed ID: 24652830
[TBL] [Abstract][Full Text] [Related]
19. (+)-[
Tiepolt S; Becker GA; Wilke S; Cecchin D; Rullmann M; Meyer PM; Barthel H; Hesse S; Patt M; Luthardt J; Wagenknecht G; Sattler B; Deuther-Conrad W; Ludwig FA; Fischer S; Gertz HJ; Smits R; Hoepping A; Steinbach J; Brust P; Sabri O
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):731-746. PubMed ID: 32935187
[TBL] [Abstract][Full Text] [Related]
20. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging.
Thambisetty M; Jeffrey Metter E; Yang A; Dolan H; Marano C; Zonderman AB; Troncoso JC; Zhou Y; Wong DF; Ferrucci L; Egan J; Resnick SM; O'Brien RJ
JAMA Neurol; 2013 Sep; 70(9):1167-72. PubMed ID: 23897112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
